FemTech Startups in India 2026: The Complete Guide to Funding, Building, and Scaling Women’s Health Technology

If you are a woman building a health, wellness, or technology product for women in India, this is the most specific guide to the sector available in 2026.

What the Data Shows About FemTech Startups in India 2026

Key insight: India’s FemTech market is growing at 28% annually, but fewer than 31% of India’s FemTech startups have received any institutional funding, indicating a structural gap between market demand and capital deployment that creates significant first-mover opportunities for well-positioned founders.

India’s 448 active FemTech startups span six primary categories. Menstrual health and hygiene represents the largest segment by company count, with brands like Nua, Sirona Hygiene, and Carmesi building consumer businesses around period care products. Fertility and reproductive health is the fastest-growing segment by funding volume, with companies like Gynoveda (which raised Rs 100 crore in 2024 at a valuation of Rs 600 crore) demonstrating that investors will write large checks when the category is de-risked by proven consumer demand. Maternal and prenatal health, mental wellness platforms for women, sexual wellness, and AI-enabled diagnostics for women-specific conditions round out the category landscape. According to Tracxn’s FemTech India report, the 22 startups that have raised Series A or beyond collectively employ over 4,000 people and serve more than 8 million monthly active users across their platforms.

The funding gap is stark and worth understanding precisely. Of India’s 448 FemTech startups, 312 have raised no institutional funding at all. This is not primarily because investors dislike the category. It is because most FemTech founders approach investors without the specific data points that de-risk a health tech investment: clinical validation, regulatory clarity, unit economics, and a clear answer to the question of why their solution creates behavior change rather than just awareness. The founders who have raised Series A+ rounds have answered these questions clearly. The founders who have not raised institutional capital typically have not. Women exploring all government funding options that can help bridge this gap before approaching VCs should read the complete guide to government loans and grants for women entrepreneurs in India.

India’s Leading FemTech Startup Categories and Companies in 2026

Menstrual Health and Period Care

India’s period care FemTech segment has produced some of the country’s most recognizable women-led consumer brands. Nua, founded by Riya Patel in 2017, has raised over Rs 75 crore and serves more than 1 million customers with customizable subscription-based period care products. Sirona Hygiene, founded by Deep Bajaj and Mohit Bajaj, has expanded into a broader women’s hygiene and wellness portfolio following its acquisition by Good Glamm Group. Carmesi, founded by Tanvi Johri, builds premium organic period products and has built a strong direct-to-consumer subscription base through Instagram-native community building. The common thread in all three: they built community before they built distribution. Each company invested in educating their target customer about product quality and health outcomes before focusing on conversion, which created brand loyalty that traditional FMCG competitors could not replicate with price competition. This community-first playbook is the most reliable growth strategy for FemTech consumer brands entering a market where the product category itself is under-discussed and under-understood. Women building in this space should also review how women-led D2C brands across India are using community and content to build consumer businesses at scale.

Fertility and Reproductive Health Technology

Fertility tech is the highest-value FemTech category in India by funding volume. Gynoveda, which uses Ayurvedic protocols to address PCOS, thyroid disorders, and fertility issues, raised Rs 100 crore in a Series B round in 2024 at a Rs 600 crore valuation, demonstrating that investors will write significant checks when a fertility product can show clinical outcomes data alongside consumer demand. The fertility tech category in India is growing rapidly for a specific demographic reason: India’s urban working women are marrying and starting families later, increasing the average age of first pregnancy and creating demand for fertility monitoring, egg freezing consultation, and IVF-adjacent digital health services. Startups building in this space in 2026 should focus on three elements that have proven to differentiate fundable from unfundable fertility tech companies: clinical validation of at least one health outcome claim, a clear regulatory pathway under India’s CDSCO (Central Drugs Standard Control Organisation) for any diagnostic product, and a unit economics model that shows positive contribution margin at an order size below Rs 5,000 per customer acquisition.

AI-Enabled Women’s Health Diagnostics

The fastest-growing FemTech sub-category in 2026 is AI-enabled diagnostics targeting conditions that disproportionately affect women but are systematically under-diagnosed in India. PCOS affects 1 in 5 Indian women of reproductive age yet 70% of cases go undiagnosed. Thyroid disorders affect 42 million Indians with a 5:1 female-to-male ratio. Endometriosis affects roughly 25 million Indian women but carries an average diagnosis delay of 7-10 years. FemTech startups building AI tools that reduce diagnosis time, improve screening accuracy, or support primary care physicians in identifying these conditions at lower cost are receiving disproportionate investor attention in 2026. The reason: diagnostic AI can demonstrate clinical validation through peer-reviewed studies, which gives health tech investors the evidence base they need to write checks. Founders building in this sub-category should budget Rs 25-50 lakh for a structured clinical validation study before approaching Series A investors, because the data from that study is the most important asset in your fundraising conversation.

How to Fund a FemTech Startup in India in 2026: Step-by-Step

Start with Non-Dilutive Government Grants

FemTech startups in India can access non-dilutive capital from three primary government sources before approaching equity investors. The Department of Biotechnology’s BIRAC (Biotechnology Industry Research Assistance Council) provides grants of Rs 25 lakh to Rs 5 crore for biotech and health-tech startups through its BIG (Biotechnology Ignition Grant) scheme. Women-led health startups receive priority consideration. The Startup India Seed Fund Scheme (SISFS) provides up to Rs 20 lakh as a proof-of-concept grant and up to Rs 50 lakh as convertible debentures through DPIIT-approved incubators. The Department of Health and Family Welfare runs a Digital Health Innovation Grant for startups building digital health solutions aligned with India’s Ayushman Bharat Digital Mission (ABDM). Women founders should apply for BIRAC BIG and SISFS simultaneously, as these programs have different selection criteria and different timelines. Combining them can provide Rs 75 lakh to Rs 1 crore in non-dilutive capital to fund clinical validation and product development before approaching angels. The MUDRA loan options for women entrepreneurs are also available for FemTech founders who need working capital to fund inventory or operations during early growth.

Target Impact Investors Before General Health Tech VCs

FemTech startups in India have a better conversion rate with impact investors than with general health tech VCs at the seed and pre-Series A stage. Impact funds like Ankur Capital, Aavishkaar Capital, and Omidyar Network India specifically track gender-lens investing and understand the FemTech market without requiring extensive category education. Pitch to impact investors first because they will move faster, ask fewer questions about TAM calculations, and provide introductions to general health tech VCs when you are ready for larger rounds. The data supports this approach: of the 22 FemTech startups in India that have raised Series A or beyond, 14 had impact fund participation in their seed or pre-seed rounds. The impact investor is frequently the first believer who provides the seed-round validation that unlocks access to the general VC community.

Build Clinical Validation Before Raising Series A

The single most common reason FemTech startups fail to raise Series A funding in India is the absence of clinical validation data. General health tech investors at the Series A stage require evidence that a product produces measurable health outcomes, not just positive user experience ratings. A well-designed clinical study with 100-200 participants, peer-reviewed by a credible academic medical institution, costs Rs 25-50 lakh and takes 6-12 months. This is not optional for health outcome products. FemTech founders who raise a seed round on product promise and community traction but spend none of that capital on clinical validation consistently struggle at Series A. Budget 30-40% of your seed round for clinical validation if your product makes any health outcome claim. The validation data is your Series A pitch.

Key Resources for FemTech Founders in India 2026

BIRAC BIG Grant provides Rs 25 lakh to Rs 5 crore for biotech and health-tech startups. Women-led FemTech startups building diagnostic, therapeutic, or digital health products are specifically encouraged to apply. Applications open on a rolling basis at the BIRAC official portal. Requires a scientific rationale document, IP plan, and team profile.

SISFS (Startup India Seed Fund Scheme) provides up to Rs 70 lakh in combined grant and convertible debenture funding through DPIIT-approved incubators. Multiple health-tech incubators including IIT Bombay’s SINE, IIM Ahmedabad’s CIIE, and NSRCEL at IIM Bangalore are DPIIT-approved and actively support FemTech applicants.

Ankur Capital and Omidyar Network India are the two most active impact investors with explicit FemTech investment mandates in India. Both have backed women’s health startups at the seed stage with tickets of Rs 1-5 crore. Building relationships with their investment teams before you need capital is the correct approach.

FemTech Association of India maintains an active community of FemTech founders, investors, and clinical advisors in India. Membership provides access to the association’s investor network, regulatory guidance from advisors with CDSCO experience, and peer community events in Bangalore, Mumbai, and Delhi. For context on how women entrepreneurs in Bangalore are building in adjacent health tech categories, see how women entrepreneurs in Bangalore 2026 are accessing NSRCEL and Karnataka’s health-tech grants.

Common Mistakes FemTech Founders in India Make

The most common mistake is conflating awareness with behavior change. A large number of Indian FemTech apps show strong download numbers and positive user reviews but fail to demonstrate that users actually change their health behavior because of the product. Investors at Series A know that downloads do not equal outcomes. If your app helps women track their cycle but does not produce a measurable improvement in health outcomes, treatment adherence, or diagnostic accuracy, you do not have a health tech product. You have a consumer app. Consumer apps have very different investor pools, very different unit economics benchmarks, and very different growth levers than health tech products. Be precise about which category you are building in before you begin fundraising.

The second mistake is underestimating CDSCO’s regulatory timeline for diagnostic products. Any FemTech product that makes a diagnostic claim, such as screening for PCOS, detecting pregnancy, or monitoring fertility hormones, falls under CDSCO’s medical device regulations and requires formal regulatory clearance. This process takes 12-24 months and costs Rs 15-30 lakh in regulatory compliance costs. Founders who build a diagnostic product without budgeting for regulatory clearance consistently miss their investor timelines and burn through seed capital during an unexpected regulatory hold. Engage a CDSCO regulatory consultant before you build the product, not after.

The third mistake is building for urban educated women only. India’s urban tier-1 FemTech consumer is intensely competed for by existing brands. The largest underserved market for women’s health products in India is semi-urban and rural women in tier-2 and tier-3 cities who have no access to quality menstrual health, maternal care, or reproductive health resources. Startups that build for this market with appropriate price points and regional language interfaces are addressing a market 10x the size of the urban FemTech consumer base and facing 90% less direct competition.

What to Expect for FemTech Startups in India Beyond 2026

India’s FemTech market is expected to see its first Rs 500 crore exits between 2026 and 2028, as the leading Series B companies from 2023-2024 approach acquisition or IPO readiness. This will create a new class of experienced FemTech founders with capital to reinvest in the next generation of women’s health startups. The regulatory environment is also improving, with the National Health Authority’s ABDM framework creating standardized digital health infrastructure that FemTech startups can build on rather than building from scratch. Women building FemTech companies in India in 2026 are entering a market that is about to experience its first significant liquidity events, which will bring more investor attention, more media coverage, and more consumer awareness than the category has ever had. For context on how FemTech intersects with broader women entrepreneurship trends across India, the guide to women-led D2C brands in India 2026 covers the consumer brand building strategies that are most transferable to FemTech’s consumer-facing products.

Frequently Asked Questions: FemTech Startups in India 2026

What is FemTech and what categories does it include?

FemTech (female technology) refers to software, diagnostics, products, and services that use technology to improve women’s health and wellness. In India, FemTech includes menstrual health and period care products, fertility and reproductive health platforms, maternal and prenatal health technology, mental wellness platforms for women, sexual wellness products, and AI-enabled diagnostics for conditions like PCOS, endometriosis, and thyroid disorders that disproportionately affect women.

How many FemTech startups are there in India in 2026?

India has 448 active FemTech startups as of 2026, of which 136 have received institutional funding and 22 have raised Series A or beyond. The sector is growing at approximately 28% annually, driven by rising consumer awareness and increasing willingness of impact investors to fund women’s health technology companies.

What is the market size of FemTech in India?

India’s FemTech market was approximately $400 million in 2024 and is projected to reach $1.2 billion by 2028, representing a compound annual growth rate of approximately 28%. Fertility tech and AI-enabled diagnostics are the fastest-growing sub-categories by funding volume, while menstrual health and period care represent the largest segment by company count.

What funding is available for FemTech startups in India?

FemTech startups can access non-dilutive government funding through BIRAC’s BIG grant (Rs 25 lakh to Rs 5 crore), the Startup India Seed Fund Scheme (up to Rs 70 lakh combined), and the Digital Health Innovation Grant from the Health Ministry. Impact investors like Ankur Capital and Omidyar Network India actively fund seed-stage FemTech startups with Rs 1-5 crore tickets.

Do FemTech diagnostic products require CDSCO approval in India?

Yes. Any FemTech product that makes a diagnostic claim, including cycle tracking for fertility prediction, PCOS screening, or pregnancy detection, falls under CDSCO’s medical device regulations and requires formal regulatory clearance. This process takes 12-24 months and costs Rs 15-30 lakh. FemTech founders should engage a regulatory consultant before building any diagnostic product.

What makes a FemTech startup investable at Series A in India?

The key criteria that Series A investors in India look for in FemTech startups are: clinical validation data from a peer-reviewed study demonstrating measurable health outcomes, positive unit economics at Rs 5,000 or less customer acquisition cost, regulatory clarity for any diagnostic claims, monthly active user growth of at least 15-20% quarter-on-quarter, and a clear path to national scale. Impact fund participation in the seed round is also a strong signal that reduces due diligence friction for general health tech VCs.